bms790052 dihydrochloride

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antivirals to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has not been convincingly implicated in cases of clinically apparent liver injury with jaundice.

Daclatasvir-[13C2,D6] (Standard) is a reference standard of Daclatasvir-[13C2,D6] intended for quantitative analysis, quality control, and related biochemical research applications.

Daclatasvir-D6 is the deuterated form of Daclatasvir. Daclatasvir (T6229) (BMS-790052) is a potent orally active inhibitor of the HCV NS5A protein, with an EC50 range of 9-146 pM across various HCV replicon genotypes. Additionally, Daclatasvir (T6229) acts as an inhibitor of organic anion transporting polypeptides 1B (OATP1B) and OATP1B3, with IC50 values of 1.5 µM and 3.27 µM, respectively.

Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.